Physician profile
Michael Mcbride
NPI 1508325697
$11,531.70
in general payments reported to CMS, 2019-2025
32 companies · $7,497 in 2025
The $7,497 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,611 · 2024: $2,424 · 2025: $7,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,077 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,076.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,455.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,966.00 | 2023-2025 | |
| Abbvie INC. | $1,232.31 | 2023-2025 | |
| Ucb, INC. | $920.47 | 2023-2025 | Bimzelx |
| Dermavant Sciences, INC. | $850.89 | 2023-2024 | Vtama |
| Leo Pharma INC. | $622.75 | 2023-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $508.52 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $451.28 | 2024-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $375.07 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $367.50 | 2023-2025 | |
| Janssen Biotech, INC. | $353.82 | 2023-2025 | Tremfya |
| Incyte Corporation | $349.26 | 2024-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $225.95 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $225.48 | 2023-2025 | Jublia, Cabtreo, Siliq |
| Pfizer INC. | $205.06 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $159.24 | 2024-2025 | Tremfya |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $108.27 | 2025 | Dupixent |
| Organon LLC | $90.81 | 2025 | Vtama |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.65 | 2024 | Duobrii, Siliq |
| Arcutis Biotherapeutics, INC. | $64.57 | 2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $64.06 | 2024 | |
| Botanix Sb INC | $47.60 | 2025 | Sofdra |
| Amgen INC. | $40.53 | 2025 | Otezla |
| Hill Dermaceuticals, INC. | $34.92 | 2025 | Tolak |
| Verrica Pharmaceuticals INC. | $31.42 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.54 | 2023 | Spevigo |
| Fresenius Kabi USA, LLC | $26.68 | 2023 | |
| Fidia Pharma USA INC. | $23.97 | 2025 | |
| Surgenex LLC | $18.49 | 2025 | Ardeograft, Surgraft, Surmatrix |
| Sandoz INC. | $18.30 | 2024 | Hyrimoz |
| Almirall LLC | $16.75 | 2025 | Seysara |
| Mayne Pharma Commercial LLC | $11.64 | 2025 | |
| Biofrontera INC. | $5.90 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.